Table 2.
HR-HPV typea |
Prevalence of atypical Pap smear test results (%, 95% CIs) according to infection with specific HR-HPV types |
|||||||
---|---|---|---|---|---|---|---|---|
1983/84 cohort (n = 659) |
1988/89 cohort (n = 599) |
|||||||
HPV status | ASC-US or more | >LSIL | CIN1+ | HPV status | ASC-US or more | >LSIL | CIN1+ | |
HPV16 |
Negative |
3.61 |
2.30 |
1.31 |
Negative |
2.52 |
0.90 |
0.90 |
(n = 609) |
(2.28-5.42) |
(1.26-3.83) |
(0.57-2.57) |
(n = 555) |
(1.39-4.20) |
(0.29-2.09) |
(0.29-2.09) |
|
Positive |
22.00 |
16.00 |
14.00 |
Positive |
9.09 |
2.27 |
4.55 |
|
(n = 50) |
(11.53-35.96) |
(7.17-29.11) |
(5.82-26.74) |
(n = 44) |
(2.53-21.67) |
(0.06-12.02) |
(0.56-15.47) |
|
HPV18 |
Negative |
4.50 |
2.95 |
2.02 |
Negative |
2.75 |
1.03 |
1.03 |
(n = 645) |
(3.03-6.39) |
(1.78-4.56) |
(1.08-3.42) |
(n = 582) |
(1.58-4.43) |
(0.38-2.23) |
(0.38-2.23) |
|
Positive |
28.57 |
21.43 |
14.29 |
Positive |
11.76 |
0 |
5.88 |
|
(n = 14) |
(8.39-58.10) |
(4.66-50.80) |
(1.78-42.81) |
(n = 17) |
(1.46-36.44) |
(0–19.51) |
(0.15-28.69) |
|
HPV31 |
Negative |
5.22 |
3.48 |
2.37 |
Negative |
2.78 |
1.04 |
1.04 |
(n = 632) |
(3.62-7.26) |
(2.19-5.22) |
(1.33-3.88) |
(n = 575) |
(1.60-4.48) |
(0.38-2.26) |
(0.38-2.26) |
|
Positive |
0 |
0 |
0 |
Positive |
8.33 |
0 |
4.17 |
|
(n = 27) |
(0–1.28) |
(0–1.28) |
(0–12.77) |
(n = 24) |
(1.03-27.00) |
(0–14.25) |
(0.11-21.12) |
|
HPV33 |
Negative |
5.05 |
3.36 |
2.29 |
Negative |
3.03 |
1.01 |
1.18 |
n = 654) |
(3.50-7.01) |
(2.11-5.05) |
(1.29-3.75) |
(n = 594) |
(1.81-4.75) |
(0.37-2.19) |
(0.48-2.41) |
|
Positive |
0 |
0 |
0 |
Positive |
0 |
0 |
0 |
|
(n = 5) |
(0–52.18) |
(0–52.18) |
(0–52.18) |
(n = 5) |
(0–52.18) |
(0–52.18) |
(0–52.18) |
|
HPV35 |
Negative |
4.88 |
3.35 |
2.13 |
Negative |
3.02 |
1.01 |
1.17 |
(n = 656) |
(3.36-6.82) |
(2.11-5.03) |
(1.17-3.55) |
(n = 597) |
(1.80-4.72) |
(0.37-2.17) |
(0.47-2.40) |
|
Positive |
33.33 |
0 |
33.33 |
Positive |
0 |
0 |
0 |
|
(n = 3) |
(0.84-90.57) |
(0–70.76) |
(0.84-90.57) |
(n = 2) |
(0–84.19) |
(0–84.19) |
(0–84.19) |
|
HPV39 |
Negative |
4.69 |
2.97 |
2.19 |
Negative |
3.06 |
1.02 |
1.19 |
(n = 640) |
(3.18-6.62) |
(1.80-4.60) |
(1.20-3.64) |
(n = 589) |
(1.82-4.79) |
(0.37-2.20) |
(0.48-2.43) |
|
Positive |
15.79 |
15.79 |
5.26 |
Positive |
0 |
0 |
0 |
|
(n = 19) |
(3.38-39.58) |
(3.38-39.58) |
(0.13-26.03) |
(n = 10) |
(0–30.85) |
(0–30.85) |
(0–30.85) |
|
HPV51 |
Negative |
4.49 |
2.72 |
1.76 |
Negative |
2.58 |
0.55 |
1.10 |
(n = 624) |
(3.00-6.42) |
(1.59-4.33) |
(0.88-3.13) |
(n = 543) |
(1.42-4.29) |
(0.11-1.61) |
(0.41-2.39) |
|
Positive |
14.29 |
14.29 |
11.43 |
Positive |
7.14 |
5.36 |
1.79 |
|
(n = 35) |
(4.81-30.26) |
(4.81-30.26) |
(3.20-26.74) |
(n = 56) |
(1.98-17.29) |
(1.12-14.87) |
(0..05-9.55) |
|
HPV52 |
Negative |
4.89 |
3.15 |
2.21 |
Negative |
2.80 |
0.70 |
1.05 |
(n = 634) |
(3.35-6.87) |
(1.94-4.83) |
(1.21-3.68) |
(n = 572) |
(1.61-4.50) |
(0.19-1.78) |
(0.39-2.27) |
|
Positive |
8.00 |
8.00 |
4.00 |
Positive |
7.41 |
7.41 |
3.70 |
|
(n = 25) |
(0.98-26.03) |
(0.98-26.03) |
(0.10-20.35) |
(n = 27) |
(0.91-24.29) |
(0.91-24.29) |
(0.09-18.97) |
|
HPV53 |
Negative |
4.43 |
2.85 |
2.06 |
Negative |
2.78 |
0.87 |
1.22 |
(n = 632) |
(2.96-6.34) |
(1.70-4.46) |
(1.10-3.49) |
(n = 575) |
(1.60-4.48) |
(0.28-2.02) |
(0.49-2.49) |
|
Positive |
18.52 |
14.81 |
7.41 |
Positive |
8.33 |
4.17 |
0 |
|
(n = 27) |
(6.30-38.08) |
(4.19-33.73) |
(0.91-24.29) |
(n = 24) |
(1.03-27.00) |
(0.11-21.12) |
(0–14.25) |
|
HPV66 | Negative |
4.25 |
2.67 |
1.89 |
Negative |
2.78 |
0.87 |
1.04 |
(n = 636) |
(2.82-6.12) |
(1.56-4.25) |
(0.98-3.27) |
(n = 575) |
(1.6-4.48) |
(0.28-2.02) |
(0.38-2.26) |
|
Positive |
26.09 |
21.74 |
13.04 |
Positive |
8.33 |
4.17 |
4.17 |
|
(n = 23) | (10.23-48.41) | (7.46-43.70) | (2.78-33.59) | (n = 24) | (1.03-27.00) | (0.11-21.12) | (0.11-21.12) |
aHPV subtypes were counted individually. In patients with multiple HR HPV infections, the data are reported for each subtype separately, e.g. a mixed HPV16/52 infection is included in the rows for both HPV16 and for HPV52.